A Phase II Study of YHI-1702 (duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma

Suzuki Kenta0 个研究点目标入组 36 人开始时间: 2021年12月28日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•1) Histologically diagnosed as Grade 1, 2 or 3a FL according to WHO classification
•2) Relapsed or refractory disease after receiving at least two prior systemic therapies
•3) At least one measurable lesion according to the Lugano classification
•4) ECOG PS of 0 to 1
•5) Written informed consent

•1) Clinically or histologically suspected to be transformation from FL to an aggressive lymphoma or diagnosed as Grade 3b FL according to WHO classification
•2) History of interstitial pneumonia or severe lung dysfunction
•3) Received prior treatment with duvelisib (Patients who were refractory to PI3K inhibitors other than duvelisib or who experienced severe adverse events during treatment with the PI3K inhibitor were also excluded.)
•4) Ongoing treatment for systemic bacterial, fungal, or viral infection
•5) Administration of medications or foods that are strong inhibitors or inducers of CYP3A within 14 days of enrollment

发起方

Suzuki Kenta